8:20 am Chairperson’s Opening Remarks
Showcasing Game-Changing ADCs With a View to Moving ADCs into Earlier Line Treatments to Improve Patient Outcomes Sooner
8:30 am Development of ENHERTU, An HER2-directed Dxd ADC, In Early Breast Cancer & Beyond
Synopsis
- Discussing Destiny-Breast03, a Phase 3 randomised study of ENHERTU versus T-DM1 in patients with HER2+ metastatic breast cancer
- Reviewing plans to develop ENHERTU in early breast cancer
- Describing plans to expand the development of ENHERTU in gastric cancer, NSCLC and other tumours
9:00 am ADC Therapeutic Window Enhancement Based on the AJICAP Chemical Site-Specific Conjugation Platform
Synopsis
- Examining how site-specific technologies are being employed in many of the next-generation ADCs due to enhancement of clinically-relevant biological properties observed in various preclinical studies
- Demonstrating a novel method of affinity peptide mediated regiodivergent antibody functionalisation that enables the synthesis of ADCs from native IgGs in a tunable and atom-precise manner
- Highlighting how both thiol-based and azide-based site-specific ADCs produced by “AJICAP” technology demonstrated an expansion of their therapeutic index compared with stochastic technology
9:30 am Exploring Tisotumab Vedotin in Frontline Cervical Cancer
Synopsis
- Showcasing Tisotumab Vedotin data from the innovaTV 204 clinical trial
- Discussing emerging Tisotumab Vedotin data as a frontline treatment
- Exploring how Tisotumab Vedotin has the possibility as a frontline treatment for cervical cancer
10:00 am Extension of toxSYN Platform with Best-in-Class Linker-Payloads Based on Validated Topiosomerase 1 Inhibitor (Exatecan) & DNA-damaging Agent (Calicheamicin)
Synopsis
- SYNtecan E™ and SYNeamicin G™ linker-payloads show excellent in vivo efficacy and tolerability
- Immunogenic cell-death driven by SYNtecan E™ ADCs corroborated in syngeneic mouse models
- Comprehensive set of linker-payloads enables matching of payload MOA to any clinical indication
10:30 am
Morning Break & Refreshments
1:00 pm
Lunch & Networking
Delving into the Development of Antibody Drug Conjugates with Novel Modes of Action
2:00 pm Antibody Targeted Amanitin Conjugates (ATAC): A New Payload Provides New Options for Cancer Therapy
Synopsis
- Discussing a new payload with a new mode of action providing new options to fight cancer
- The ATAC platform optimized the ADC technology for that payload
- HDP-101 targeting BCMA is the first ATAC which cleared IND and is now in dose escalation in myeloma patients
2:30 pm Modulating the Therapeutic Activity of ADCs & SMDCs With Engineered Cytokine Products
Synopsis
- Understanding how the therapeutic activity of ADCs and SMDCs can be potentiated with certain antibody-cytokine fusion proteins
- Illustrating how antibody-cytokine fusions, based on interleukin-2 and capable of selective localisation at the tumour site, are particularly effective in boosting the activity of ADCs and SMDCs
- Discussing the role of NK cells and of T cells
3:00 pm Designing Immune-Stimulating Antibody Conjugates
Synopsis
- Overview of Bolt’s Immune-Stimulating Antibody Conjugates (ISAC) technology platform as the next step in ADC-based immune therapy
- Highlighting the key features and the mechanism of action
- Demonstrating the use of various methods to understand and design potent ISACs
3:30 pm
Afternoon Refreshments
Analysing Innovative Technologies to Progress the Next Generation of ADCs
4:00 pm Novel In Vitro Screening Assays for ADC Characterisation & Stability Assessment
Synopsis
- Exploring new approaches to characterise ADCs In Vitro
- Outlining how this technology can be leveraged to design best-in-class ADCS
*Virtual Speaker*
4:30 pm Introduction of a Novel Topoisomerase-I Inhibitor ADC Platform
Synopsis
- Discussing design and characterization of payloads and ADCs including potency, specificity, bystander activity, and biophysical characteristics
- Evaluating ADCs against multiple tumor targets demonstrating strong anti-tumor activity in xenograft models
- Sharing encouraging data in multiple preclinical tolerability studies
5:00 pm Strategically Developing & Advancing ADCs
Synopsis
*Virtual*
- Providing an historical review of ADCs
- Overviewing the current ADC landscape
- Discussing the future of ADCs: Combinations and Sequencing